000 03845nam a22005655i 4500
999 _c200457265
_d75477
003 DE-He213
005 20231109085800.0
007 cr nn 008mamaa
008 220512s2022 sz | s |||| 0|eng d
020 _a9783030963767
024 7 _a10.1007/978-3-030-96376-7
_2doi
040 _aTR-AnTOB
_beng
_cTR-AnTOB
_erda
060 4 _aQZ 266
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
072 7 _aMJCL
_2thema
096 _aQZ266EBK
245 1 0 _aCancer Immunotherapies
_h[electronic resource] :
_bSolid Tumors and Hematologic Malignancies /
_cedited by Priya Hays.
250 _a1st ed. 2022.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2022.
300 _a1 online resource
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCancer Treatment and Research,
_x2509-8497 ;
_v183
505 0 _aDevelopment of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia.-Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies.
520 _aThis book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.
650 0 _aOncology.
650 0 _aHematology.
650 0 _aGenetics.
650 0 _aGenomics.
650 1 4 _aOncology.
650 2 4 _aHematology.
650 2 4 _aGenetics.
650 2 4 _aGenomics.
653 0 _aNeoplasms -- immunology
653 0 _aNeoplasms -- therapy
653 0 _aImmunotherapy
700 1 _aHays, Priya.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
830 0 _aCancer Treatment and Research,
_x2509-8497 ;
_v183
856 4 0 _uhttps://doi.org/10.1007/978-3-030-96376-7
_3Springer eBooks
_zOnline access link to the resource
942 _2NLM
_cEBK
041 _aeng